Neurocrine Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBIX research report →
Companywww.neurocrine.com
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.
- CEO
- Kyle W. Gano
- IPO
- 1996
- Employees
- 1,800
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $15.47B
- P/E
- 23.12
- P/S
- 4.99
- P/B
- 4.54
- EV/EBITDA
- 17.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.17%
- Op Margin
- 25.19%
- Net Margin
- 21.55%
- ROE
- 21.64%
- ROIC
- 13.68%
Growth & Income
- Revenue
- $2.86B · 21.45%
- Net Income
- $478.60M · 40.23%
- EPS
- $4.81 · 41.47%
- Op Income
- $619.10M
- FCF YoY
- 34.37%
Performance & Tape
- 52W High
- $162.39
- 52W Low
- $117.59
- 50D MA
- $135.21
- 200D MA
- $138.45
- Beta
- 0.34
- Avg Volume
- 1.15M
Get TickerSpark's AI analysis on NBIX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | POPS RICHARD F | other | 15,000 |
| May 15, 26 | POPS RICHARD F | sell | 15,000 |
| May 15, 26 | POPS RICHARD F | other | 15,000 |
| May 12, 26 | Norwalk Leslie V | sell | 3,810 |
| Mar 15, 26 | Ratz Andrew | other | 0 |
| Mar 15, 26 | Ratz Andrew | other | 2,664 |
| Mar 15, 26 | Ratz Andrew | other | 5,640 |
| Mar 15, 26 | Ratz Andrew | other | 17,724 |
| Mar 15, 26 | Ratz Andrew | other | 805 |
| Mar 15, 26 | Ratz Andrew | other | 31,348 |
Our NBIX Coverage
We haven't published any research on NBIX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NBIX Report →